Cinnarizin, tablets 25 mg 50 pcs

Indications

Chronic cerebrovascular insufficiency (dizziness, tinnitus, headache, memory impairment, decreased concentration).
Vestibular disorders (including Meniere’s disease, dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinthine origin).
Prevention of kinetosis (“road sickness” – sea and air sickness).

Migraine (prevention of attacks).

Peripheral circulation disorders (intermittent claudication, Raynaud’s disease, diabetic angiopathy, thrombophlebitis, trophic disorders, including trophic and varicose ulcers).

Pharmacological effect

Pharmaceutical group:

blocker of “slow” calcium channels.

Pharmaceutical action:

Selective BMCC reduces the entry of Ca2+ into cells and reduces their concentration in the plasma membrane depot, reduces the tone of the smooth muscles of arterioles, and enhances the vasodilating effect of carbon dioxide.

Directly affecting the smooth muscles of blood vessels, it reduces their response to nutrients (adrenaline, norepinephrine, dopamine, angiotensin, vasopressin). It has a vasodilating effect (especially in relation to cerebral vessels), without having a significant effect on blood pressure.

It exhibits moderate antihistamine activity, reduces the excitability of the vestibular apparatus, and lowers the tone of the sympathetic nervous system.

Effective in patients with latent cerebral circulatory failure, initial cerebral atherosclerosis and chronic cerebral vascular diseases with post-stroke focal symptoms.

In patients with impaired peripheral circulation, it improves blood supply to organs and tissues (including the myocardium), enhances post-ischemic vasodilation.

Increases the elasticity of red blood cell membranes, their ability to deform, and reduces blood viscosity. Increases muscle resistance to hypoxia.

Pharmacokinetics:

TCmax after oral administration – 1-3 hours, binding to plasma proteins – 91%.
Completely metabolized in the liver (via dealkylation). T1/2 – 4 hours
Excreted in the form of metabolites: 1/3 – by the kidneys and 2/3 – with feces.

Special instructions

Due to the presence of an antihistamine effect, cinnarizine can affect the results of anti-doping control of athletes (false-positive results), as well as neutralize positive reactions during skin diagnostic tests (treatment should be discontinued 4 days before the test).

With long-term use, it is recommended to conduct a control examination of liver function, kidney function, and peripheral blood patterns.
Women taking cinnarizine are not recommended to breastfeed.

Patients with Parkinson’s disease should be prescribed only in cases where the benefits of its use outweigh the possible risk of worsening the condition.

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Cinnarizine

Composition

Cinnarizine 25 mg.

Contraindications

Hypersensitivity, pregnancy, lactation, children under 5 years of age.

With caution. For dosage forms containing lactose (additionally): lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome.

Side Effects

From the nervous system: drowsiness, increased fatigue, headache, extrapyramidal disorders (tremor of the limbs and increased muscle tone, hypokinesia), depression.

From the digestive system: dryness of the oral mucosa, pain in the epigastric region, dyspepsia, cholestatic jaundice.

From the skin: increased sweating, lichen planus (extremely rare).

Allergic reactions: skin rash.

Other: decreased blood pressure, increased body weight, lupus-like syndrome.

Interaction

Strengthens the effect of ethanol, sedatives, tricyclic antidepressants.

Overdose

Symptoms: vomiting, drowsiness, tremor, excessive decrease in blood pressure, coma.

Treatment: there is no specific antidote, gastric lavage, activated charcoal, symptomatic therapy.

Manufacturer

Pharma AD, Bulgaria